APLS
Apellis Pharmaceuticals, Inc.
Key Financials
Operating Income
$55.4M
↑ 133.6%
Net Income
$22.4M
↑ 111.3%
Revenue
$1.0B
↑ 28.5%
Total Liabilities
$705.1M
↑ 7.4%
Total Assets
$1.1B
↑ 21.5%
EPS (Diluted)
$0.20
↑ 112.5%
Shareholders' Equity
$370.1M
↑ 62.0%
Long-term Debt
$93.0M
↑ 0.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SC 14D9 | 4/14/2026 | View on SEC |
| SC TO-T | 4/14/2026 | View on SEC |
| 4 | 4/8/2026 | View on SEC |
| SC TO-C | 4/7/2026 | View on SEC |
| SCHEDULE 13G/A | 4/7/2026 | View on SEC |
| 3 | 4/6/2026 | View on SEC |
| SCHEDULE 13D | 4/6/2026 | View on SEC |
| SC14D9C | 4/6/2026 | View on SEC |
| SC TO-C | 4/3/2026 | View on SEC |
| SC14D9C | 3/31/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | APLS |
| Company Name | Apellis Pharmaceuticals, Inc. |
| CIK | 1492422 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-977-5700 |